Search
for
Sort by
Research 961–990 of 1000+
- CD27 and IL-35 as diagnostic biomarkers in alopecia areata: First evidence of association with pathogenic scalp bacterial infections
- Impacto del desequilibrio del microbioma del cuero cabelludo en la severidad de la alopecia areata, marcadores inflamatorios y cambios post-tratamiento
- Recent advances in the genetics of alopecia areata
- Recommendations on trichological treatments during COVID-19 pandemic
- Melatonin preparations in dermatological practice
- Teriflunomide efficacy, safety and tolerability in patients with relapsing forms of multiple sclerosis
- Clinical Management in Psychodermatology
- Ethical Principles for Everyone
- Blinding in Placebo-Controlled Trials
- Severe cutaneous adverse reactions to drugs
- Efficacy of tofacitinib in treatment of alopecia universalis in two patients
- Adult skin acute stress responses to short‐term environmental and internal aggression from exposome factors
- Benefit-Risk Assessment of GLP-1 Receptor Agonists: Implications for Dermatologists and Plastic Surgeons
- Influence of The Anabolic Steroid Usage on The Physical Health: A Review
- Calcipotriene plus betamethasone dipropionate gel: a new combination therapy for scalp psoriasis
- Ayurveda-Based Supportive Care Using Guduchi, Ashwagandha, and Curcumin for Breast Cancer Patients: A Pilot Observational Study on Quality of Life and Safety
- Emerging smart microneedle technologies in psoriasis: convergence of nanocarriers, machine learning, and personalized delivery
- Improvement of Recalcitrant Folliculitis Decalvans With Tirzepatide: A Case Report
- Amla: An ancient medicinal plant with wide-ranging properties
- The evaluation of IL-4 VNTR intron 3 and TNF-α (rs1799964) gene polymorphisms in Egyptian patients with alopecia areata: a case–control study
- The evaluation of IL-4 intron 3 VNTR and TNF-α (rs1799964) gene polymorphisms in Egyptian patients with Alopecia Areata: a case-control study
- Journal for ReAttach Therapy and Developmental Diversities
- Subject Index
- Alopecia areata
- Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata
- Ritlecitinib: First Approval
- Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
- Lupus panniculitis clinically simulating alopecia areata
- Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects
- Localized cutaneous necrosis associated with the antiphospholipid syndrome